Therapie der akuten Manie

Zusammenfassung

Gegenstand und Ziel: Dieser Artikel soll einen Überblick über die Möglichkeiten der pharmakologischen Behandlung der akuten Manie geben. Material und Methoden: Mithilfe einer selektiven Literaturrecherche in Pubmed wurden Studien identifiziert, welche die Wirksamkeit der medikamentösen Therapie einer manischen Episode im Rahmen einer bipolaren affektiven Störung I untersuchen. Zudem wurden die verfügbaren Studien zu den neu zugelassenen Substanzen einbezogen. Ergebnisse: Die aus den Arbeiten resultierenden Empfehlungen wurden für die einzelnen zugelassenen oder von Fachgesellschaften empfohlenen Substanzen zusammengestellt und erläutert. Lithium, Valproinsäure und verschiedene atypische Antipsychotika sind zur Therapie der akuten Manie zugelassen und wirksam. Die Auswahl für eine Substanz sollte verschiedene Überlegungen zum klinischen Subtyp der Manie und zu unerwünschten Wirkungen der einzelnen Pharmaka beinhalten.

Summary

Objective: This article is intended to provide an overview of possible pharmacological treatments of acute mania. Materials and methods: A selective search of the literature in pubmed helped to identify studies examining the effectiveness of medicinal therapy of manic episodes in the context of a bipolar affective disorder I.Available studies on recently licensed substances were also included. Results: The recommendations resulting from the above-mentioned papers were compiled and elucidated for each for each substance licensed or recommended by medical societies. Lithium, valproic acid and various atypical antipsychotics are licensed and effective against acute mania. The choice of a substance should be based on various deliberations regarding the clinical subtype of mania and the undesirable effects of each drug.

Schlüsselwörter

Akute Manie - Pharmakotherapie

Keywords

Acute mania - pharmacological treatment

• Literatur

• 1 Yatham LN. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-25.
• 2 www.nice.org.uk/CG038 (1. Februar 2011).
• 3 Foster S, Kessel J, Berman M, Simpson G. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12: 175-9.
• 4 Currier G. et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65: 386-94.
• 5 Tamayo JM, Zarate Jr CA, Vieta E, Vázquez G, Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and metaanalysis. Int J Neuropsychopharmacol 2010; 13 (06) 813-2.
• 6 Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebocontrolled trials. Bipolar Disord 2007; 09: 551-60.
• 7 Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442-55.
• 8 Bowden C. et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271: 918-24.
• 9 Macritchie K. et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003; CD004052.
• 10 Latham LN. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 07 (Suppl. 03) 65-9.
• 11 Yatham LN. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 08: 721-39.
• 12 Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother 2005; 05: 297-307.
• 13 Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004; 10: 317-36.
• 14 Zimbroff DL. et al. Management of acute agitation in patients with bipolar disorder. Efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacology 2007; 27 (02) 171-6.
• 15 Keck Jr PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Sana A. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-8.
• 16 Vieta E, Bourin M, Sánchez R, Marcus R, Stock E, McQuade R. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomised, comparative 12 week trial. Br J Psychiatry 2005; 187: 235-42.
• 17 Suppes T, Eudicone J, McQuade R, Pikalov 3rd A, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Affect Disord 2008; 107 (1–3): 145-54.
• 18 Vieta E, T´joen C, McQuade RD, Carson Jr WH, Marcus RN, Sanchez R, Owen R, Nameche L. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165 (10) 1316-22.
• 19 Muzina DJ, Momah C, Eudicone JM, Pikalov A, McQuade RD, Marcus RN, Sanchez R, Carlson BX. Aripiprazole monotherapy in patients with rapidcyling bipolar I disorder: an analysis form a longterm, double-blind, placebo-controlled study. Int J Clin Pract 2008; 62 (05) 679-87.
• 20 Keck Jr PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-91.
• 21 Young AH. et al. Aripiprazol monotherapy in acute mania: 12 week, randomized, placebo and haloperidol-controlled study. The British Journal of Psychiatry 2009; 194 (01) 40-48.
• 22 Keck Jr PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-37.
• 23 Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placeboand lithium-controlled study. J Affect Disord 2009; 112 (1–3): 36-49.
• 24 Sachs G, Sánchez R, Marcus R, Stock E, McQuade R, Carson W. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I © Schattauer 2011 Nervenheilkunde 5/2011 disorder: a 3 week placebocontrolled study. J Psychopharmacol 2006; 20: 536-46.
• 25 Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004; 16: 189-94.
• 26 Papakostas Gl, Petersen TJ, Kinrys G, Burns AW, Worthington JJ, Alpert JE. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 1326-30.
• 27 Fachinformation Aripiprazol.
• 28 Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolare Disorder 2005; 07 (Suppl. 04) 21-33.
• 29 Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacother 2009; 29 (01) 64-73.
• 30 Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90.
• 31 Ali S, Pearlman RL, Upadhyay A, Patel P. Neuroleptic malignant syndrome with aripiprazole and lithium: a case report. J Cin Psychopharmacol 2006; 26: 434-6.
• 32 Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007; 30: 47-51.
• 33 Sachs GS, Gaulin BD, Gutiérrez-Esteinou R, McQuade RD, Pikalov III A, Pultz JA. Antimanic response to aripiprazole in bipolar I disorder patients in independent of the agitation level at baseline. J Clin Psychiatry 2007; 68: 1377-83.
• 34 Cutler A. et al. Effectiveness of extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania (trial D144CC00004) Abstract NR3–006. Annual meeting of the American Psychiatric Association. Washington, D.C. 2008
• 35 Al Jurdi RK, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat 2010; 06: 29-35.
• 36 Hirschfeld R. et al. Asenapine in acute mania: a randomized, double-blind, placeboand olanzapinecontrolled trial (Ares 7501005) Abstract NR333. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association 2007
• 37 Panagides J. et al. Asenapine in acute mania: a randomized, double-blind, placeboand olanzapinecontrolled trial (ARES 7501004). Biol Psychiatry 2007; 61: 222S.
• 38 McIntyre R, Hirschfeld R, Alphs L, Cohen M, Macek T, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: outcomes from two randomized placebo-controlled trials. Bipolar Disord 2008; 10 (Suppl. 01) 49.
• 39 Sycrest 10 mg Sublingualtabletten Fachinformation, Stand 9/2010 www.fachinfo.deam1 Februar 2011..
• 40 Calabrese J, Cohen M, Zhao J, Panagides J. Efficacy and safety of asenapine as adjunctive treatment for acute mania associated with bipolar disorder Abstract NR3–061. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association 2008
• 41 Manji HK, Lenox RH. Protein Kinase C signalling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328-51.
• 42 Singer CA. et al. Dorsa, estrogen protects primary cortical neurons from glutamate toxicity. Neurosci 1996; 212: 13-6.
• 43 Kulkarni J, Garland KA, Scaffidi A, Headey B, Anderson R, de Castella A, Fitzgerald P, Davis SR. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31 (04) 543-7.
• 44 Wagner KD. et al. A doubleblind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163: 1179-86.
• 45 Akhondzadeh S, Milajerdi MR, Amini H, TehraniDoost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a doubleblind, randomized, placebo-controlled trial. Bipolar Disord 2006; 08: 485-89.
• 46 Lakshmi NY. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-55.